Target
Mitogen-activated protein kinase 9
Ligand
BDBM50333995
Substrate
n/a
Meas. Tech.
ChEMBL_701206 (CHEMBL1648826)
IC50
2000±n/a nM
Citation
 Probst, GDBowers, SSealy, JMTruong, APHom, RKGalemmo, RAKonradi, AWSham, HLQuincy, DAPan, HYao, NLin, MTóth, GArtis, DRZmolek, WWong, KQin, ALorentzen, CNakamura, DFQuinn, KPSauer, JMPowell, KRuslim, LWright, SChereau, DRen, ZAnderson, JPBard, FYednock, TAGriswold-Prenner, I Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett 21:315-9 (2010) [PubMed]  Article 
Target
Name:
Mitogen-activated protein kinase 9
Synonyms:
JNK-55 | JNK2 | JNK2/JNK3 | MAPK9 | MK09_HUMAN | Mitogen-Activated Protein Kinase 9 (JNK2) | Mitogen-activated protein kinase 8/9 | PRKM9 | SAPK1A | Stress-activated protein kinase JNK2 | c-Jun N-terminal kinase 2 | c-Jun N-terminal kinase 2 (JNK2)
Type:
Enzyme
Mol. Mass.:
48131.49
Organism:
Homo sapiens (Human)
Description:
JNK-2 was purchased from Upstate Cell Signaling Solutions (formerly Upstate Biotechnology).
Residue:
424
Sequence:
MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR
  
Inhibitor
Name:
BDBM50333995
Synonyms:
1-(1-ethylpiperidin-4-yl)-4-(naphthalen-2-yl)-3-(2-(tetrahydro-2H-pyran-4-ylamino)pyridin-4-yl)-1H-1,2,4-triazol-5(4H)-one | CHEMBL1644644
Type:
Small organic molecule
Emp. Form.:
C29H34N6O2
Mol. Mass.:
498.6193
SMILES:
CCN1CCC(CC1)n1nc(-c2ccnc(NC3CCOCC3)c2)n(-c2ccc3ccccc3c2)c1=O
Structure:
Search PDB for entries with ligand similarity: